bioAffinity Technologies, Inc. (BIAFW) Aandelenanalyse

Bedrijfsoverzicht

bioAffinity Technologies, Inc. is a specialized entity focused on the development of non-invasive diagnostic laboratory tests designed to detect early-stage lung cancer and various other pulmonary diseases utilizing flow cytometry and automated analysis techniques within the United States market. The company operates within a sector and industry classification that remains unlisted in the provided financial data, suggesting a niche positioning where traditional sector categorization may not fully capture its specific technological focus. In terms of operational scale, bioAffinity employs a workforce of 57 individuals and maintains a market capitalization and annual revenue figures that are not disclosed in the current dataset, alongside a reported trailing twelve-month revenue of $6.16 million. The absence of specific market cap data precludes a direct comparison to peer group averages, while the $6.16 million in revenue indicates a mid-sized operational footprint that relies heavily on research and development outputs rather than established mass-market sales volume. This scale, characterized by a small employee base and limited disclosed valuation multiples, reflects the typical profile of a pre-commercialization or early-stage biotechnology firm where revenue generation is still maturing alongside the advancement of its diagnostic technology platform.

Financiële gezondheid

The company reported a revenue of $6.16 million over the trailing twelve months, yet this top-line figure is associated with a net income loss of $14,909,754, revealing a significant gap between gross sales and final profitability that points to substantial operating expenses, likely driven by R&D costs and general administrative overhead. EBITDA stands at $-10,067,672, further illustrating that the company's core operations are currently generating negative cash earnings before interest, taxes, depreciation, and amortization. Free cash flow is recorded at $-4,933,569, which indicates that the company is burning through its liquidity reserves to fund its growth initiatives and technology development rather than generating surplus cash for distribution to shareholders. The gross margin stands at 31.4%, suggesting that the cost of goods sold consumes approximately two-thirds of each sales dollar, while the operating margin of -196.9% and profit margin of -242.0% demonstrate that operating expenses far exceed the gross profit generated by sales. On the balance sheet, the company holds $6.45 million in cash against $1.16 million in debt, creating a net cash position, although the debt-to-equity ratio of 15.95 implies a high level of leverage relative to shareholder equity. The current ratio of 2.60 indicates that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, suggesting a degree of short-term liquidity comfort despite the net loss position. Return on equity is reported at -301.8% and return on assets at -75.6%, metrics that reveal that management is currently reducing shareholder value and utilizing assets inefficiently in terms of generating profit, a common characteristic of companies in the early phases of product commercialization that have yet to achieve profitability.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, which implies that traditional earnings-based valuation metrics are not applicable and that any future expected earnings trajectory must be assessed based on non-GAAP measures or revenue growth potential. The price-to-book ratio is 0.23, indicating that the market values the company's equity at roughly 23% of its book value, which suggests a significant market discount often seen in speculative biotechnology stocks or those facing profitability challenges. Price-to-sales and EV/EBITDA multiples are also not available for calculation as the net income and EBITDA figures are negative, preventing a direct valuation comparison with profitable peers. The stock's 52-week high is $0.40 and the 52-week low is $0.37, meaning the current trading price sits within this narrow range, fluctuating between approximately 0% and 25% below the yearly peak depending on the specific trading day. The beta value is -0.81, a negative figure that is highly unusual for equities and suggests an inverse correlation with the broader market, implying that the stock price may move in the opposite direction of the general market index during periods of volatility. This negative beta indicates extreme price sensitivity that deviates from standard market risk models, potentially driven by specific sector-wide headwinds or unique trading dynamics affecting this particular security.

Growth & Income

Revenue growth year-over-year is -27.8%, while earnings growth is N/A due to the loss position, indicating that the company is currently shrinking in terms of sales volume rather than expanding its top line. Because the company is not generating positive earnings, there is no dividend yield or payout ratio to evaluate for sustainability, as the firm is retaining all available cash to fund its operations and reduce the negative burn rate. As a non-dividend payer, the company reinvests its limited cash flow of $-4,933,569 directly into its research and development efforts rather than distributing income to shareholders, a strategy typical for firms attempting to bring a diagnostic product to market. The overall growth and income profile is characterized by negative revenue momentum and an absence of income distribution, highlighting the company's current reliance on external capital or cash reserves to sustain operations until revenue growth turns positive.